Society has increasingly high expectations for ethical behavior from global healthcare companies – expectations that very often go beyond what is legally required. We are taking steps to ensure our standards align with these expectations.
“Our mission at Sandoz is to pioneer access to medicines and this means safeguarding equitable access to high-quality medications. To achieve our mission, we prioritize diversity and inclusion in our culture, uphold our social commitment, and drive initiatives for equity with our associates, our patients, our customers, and our suppliers. We recognize that embracing diversity, fostering inclusion and insisting on equity, is more than just "doing the right thing." This is the way to sustain a company culture that is innovative, competitive and connected to our communities. Sandoz's mission and purpose contributes to society's ability to help people around the world and this is only possible because of our relentless focus on innovation and diversity. To achieve our commitment to diversity and inclusion, society, and equity, Sandoz prioritizes a diverse workforce and grants preference to collaborators and suppliers who embrace these important and vital values.”
President, Sandoz Us
Ethics, Risk & Compliance
We are committed to creating a culture of integrity and trust through strict adherence to the Novartis Code of Conduct
To the best of our knowledge, as of January 1, 2021, Sandoz is in material compliance with its Comprehensive Compliance Program and the requirements of the California Health & Safety Code. It is Sandoz’s expectation that all employees and contractors comply with its Comprehensive Compliance Program and all policies that support the program. Sandoz is committed to assessing ongoing compliance with its Comprehensive Compliance Program, which is designed to prevent, detect and address potential or actual instances of non-compliance.
We are committed to transparent reporting – a central part of our UN Global Compact obligations. Our Annual Report serves as our primary reporting mechanism for corporate responsibility, and we have published a combined financial and CR report since 2000.
The CR Performance Report is based on the Global Reporting Initiative G4 guidelines, with disclosure at “comprehensive” level, making it the first comprehensive level-report in the healthcare industry.
The Physician Payments Sunshine Act was enacted by Congress in 2010 as part of the healthcare reform law. The Sunshine Act is intended to make relationships between certain pharmaceutical and device manufacturers and healthcare providers more transparent, by requiring applicable manufacturers to report payments and other "transfers of value" provided to physicians and teaching hospitals to the Centers for Medicare and Medicaid Services (CMS). Learn more >